Recent

% | $
Quotes you view appear here for quick access.

Keryx Biopharmaceuticals Inc. Message Board

mgm2020 400 posts  |  Last Activity: May 26, 2016 5:11 PM Member since: Mar 3, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • This is a clip from Cancer Discovery's website citing industry research: "
    According to Thomson Reuters' Journal Citation Report® (JCR; Thomson Reuters 2015):
    • Cancer Discovery's Impact Factor has increased to 19.453 from 15.929!
    • Cancer Discovery is now ranked 5th of 211 journals with regards to Impact Factor in the Oncology category "

    Apparently when you want to be recognized and have an impact in the oncology field---you get your article published in Cancer Discovery. TROV knows what they are doing, and oncologists will be paying attention.

    Sentiment: Strong Buy

  • Reply to

    Trading like ...

    by minnesotafarmcountry Apr 15, 2016 1:20 PM
    mgm2020 mgm2020 Apr 15, 2016 1:39 PM Flag

    Yes it is. No suspicious high volume spike--just orderly accumulation ahead of ?????? Now if it can stay above the 200DMA and establish that as a new floor, that would be appreciated.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Apr 15, 2016 1:15 PM Flag

    K4s---you are nothing but a little troll that knows nothing about TROV. I don't mind your posts, though, because they never have any substance or indicate any knowledge whatsoever. Just a typical know-nothing troll.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Apr 15, 2016 1:11 PM Flag

    And anyone that invested with David Einhorn saw him out $260 MILLION into SUNE and now he has a seat on the BOD. Why don't you message him?

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Apr 15, 2016 11:31 AM Flag

    You are wrong. TROV is the leader in the mutations that PCM can test and QUANTIFY----that is something that NO blood test can currently do. Other blood tests, as I have said, can DETECT and diagnose cancer, however, NONE can do it from URINE, and NONE can show longtitudinal treatment effectiveness in as little as a FEW HOURS after treatment initiation, and a single blood draw is NO GUARANTEE of capturing enough ctDNA to guarantee a diagnosis while a urine draw of 20 times the volume will provide much more information. This is how paradigm shifts occur in medicine.

    Sentiment: Strong Buy

  • Reply to

    mgm or anyone else

    by s_maisano Apr 15, 2016 10:35 AM
    mgm2020 mgm2020 Apr 15, 2016 11:25 AM Flag

    I spoke to Bob after the WM data was released and he said that the DLBCL participating MD's were very excited and enrollment was moving rapidly. I do believe that Milano said this year at Needham, as well as the data from 2 cohorts of the 2125 trial. I would like to see the company reach the first goal in the GSK partnership and receive another milestone payment. A few more partnerships would certainly relieve some of the financial concerns---which are really not material until 2017.

    Sentiment: Strong Buy

  • Reply to

    mgm or anyone else

    by s_maisano Apr 15, 2016 10:35 AM
    mgm2020 mgm2020 Apr 15, 2016 10:51 AM Flag

    Company hasn't said specifically, but Milano said "this year" at Needham.

    Sentiment: Strong Buy

  • Reply to

    If you believe MGM really owns all this stock

    by jk4763 Apr 15, 2016 9:53 AM
    mgm2020 mgm2020 Apr 15, 2016 10:10 AM Flag

    I've owned it for quite a while. I own it now, and I'm buying at this price. The DLBCL data will show exactly the same positive results as the WM data----adding confirmation and validation. The first 2 cohorts of 2125 will be completed and be available this year and that data will be as amazing as the preclinical data. If you believe the price will stay down when that data show conclusively that 2125 in combination with the FIRST of many checkpoint inhibitors it can be used with is one of the most powerful cancer treatments to be seen in a while, then------don't own this stock and get lost. What happened WITH SUNE-----and not to me----has nothing to do with the success that Idera will have. But your harping on what SUNE did-----not me--merely shows that you have always, and still have an obsession with me and lead a very sad, sad life. WHY would I continue to post positively on a board of a stock I don't own?

    Sentiment: Strong Buy

  • Other tests may be able to "detect" certain forms of cancer----and from a very limited draw of blood, but not only can TROV's PCM test detect certain forms of cancer, but much more importantly---and much more critical now to a patient's likelihood of survival---it can DETECT AND QUANTIFY the critical mutations in the patient's cancer that steer the oncologist to make the right treatment decision AS SOON AS POSSIBLE-----and alert that doctor very quickly as to whether that treatment is working or not. Not only is that something that few, if any other liquid biopsy tests can do---but NONE of them can do it from a urine sample that has a longer time period to accumulate in the bladder so it contains MUCH MORE ctDNA than ANY blood test and thus is more precise, accurate, and provides much more critical information to the doctor. This is why TROV's PCM test will be the number one choice for oncologists and why the stock is a STEAL at this price.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Apr 15, 2016 8:52 AM Flag

    Everyone should read this post---and buy.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Apr 14, 2016 4:59 PM Flag

    oops. tsum eb ym lisdexia.

    Sentiment: Strong Buy

  • Reply to

    The best part of the recent run...

    by mannchris686 Apr 14, 2016 4:26 PM
    mgm2020 mgm2020 Apr 14, 2016 4:58 PM Flag

    That would be very bullish. And to d it following the turmoil of a few weeks ago would indicate strong support and market confidence that the stock is headed higher. I believe the board will select a very good candidate for CEO, and even without one right now, the temporary CEO(from the BOD) has extensive experience as a former CEO and likely nearly as deep a knowledge of the company as Schuh. Like I said---an announcement could come at any time and we will be rewarded.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Apr 14, 2016 3:05 PM Flag

    Oh wait---here it comes! Wait----people are BUYING!! Wait----HERE it comes----nope---still buying. Maybe someone knows that an announcement is imminent????

    Sentiment: Strong Buy

  • extremely informative-and bordering on excited during the Needham presentation. Especially when it came to all of the possible uses of 2125 and all of the different checkpoint inhibitors it has shown synergistic effects with. First there was CTLA4, then PD1, and now 95% TUMOR GROWTH REDUCTION with an IDO1 inhibitor! This will be presented at AACR and in a formal press release soon. He acknowledged that preclinical data is very important, but real human data is what will drive 2125 and Idera forward, but he also said that enrollment in the 2125 study was going "extremely well and they were planning on expanding the trial to additional sites. Now-the team at MD Anderson KNOWS who is getting 2125, and these patients are relapsed and are basically at the end of their ropes. I do not believe that MD Anderson would give these patients "false" hope, and rapid enrollment, I believe, is indicative of the likelihood that 2125/Ipilumimab will work for these patients. Milano also said that the company has developed a "proprietary algorithm" that allows them to "rapidly identify" disease candidates for the 3GA compounds. They have a very strong patent that was issued in 2013 for 3GA, and he stated that with 3GA they are "building for the future of the company" and, since he is a businessman and not a scientist---thinking about the endgame, which is commercialization of the compounds and the drugs. He said that with 3GA the company will be able to "leverage that business into MULTIPLE PARTERSHIPS", and that the GSK partnership is already 14 months AHEAD of schedule! He also said that the company expects to have the data from the 1st 2 COHORTS in the 2125 study available as well as the DLBCL trial, which the company is also amending to add higher doses of 8400 to and sees as a bigger opportunity than WM. He also spoke about the advantages of Idera's 3GA platform over anything available so far. Right now---everything is positive EXCEPT the stock price--but that will change

    Sentiment: Strong Buy

  • following the adcom that Nuplazid will be approved, and this is because INVESTORS still see impressive upside to the price. And those investors include the Bakers who added over a million more shares following the 21-2 vote in favor of approval. Now you can add Adam Feuerstein(who I really don't out much credence behind) to the long list of people saying that ACAD is one of the most likely takeover targets in the market. Now---if you think that he can cause a stock to drop when he tweets or posts something negative, then you also have to think that he can have the opposite effect when he is positive. Now-----WHO is going to be selling on the news of approval, when you KNOW there is a possibility-----and here, a much greater possibility than with other pharma stocks with newly approved drugs-----that the company will announce a buyout literally within days of approval? The company could actually be fielding offers right now leading UP to the announcement. I LIKE this price action, I like the lower short interest, I like the Baker Brothers buy, I like the Bakers having a seat on the BOD, and I LOVE the potential for this stock to DOOUBLE from here following approval. I do not have a problem with ACAD garnering a $6 billion market cap PRIOR to a buyout.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Apr 14, 2016 1:02 PM Flag

    Don't tell us that you sold because of the CEO kerfuffle and are now hoping that the stock drops back down? There will be no bear raid. Another major announcement could come at any time. Those could include a major BIG-NAME panel inclusion such as Humana, The Blues, Aetna, or the biggest one-----Medicare. A new CEO could be announced at any time also. You want to be short when either of those announcements come out?

    Sentiment: Strong Buy

  • Reply to

    approvaBLE means UP or DOWN?

    by matwizemann Apr 13, 2016 9:00 PM
    mgm2020 mgm2020 Apr 14, 2016 12:58 PM Flag

    That would have been addressed with the adcom and they would have indicated they favored a delay----which they didn't and voted 12 to 2 to recommend NUPLAZID be approved. The questions you pose(foolishly) were answered during the all-day meeting.

    Sentiment: Strong Buy

  • a major run higher into and over the summer-----and for quite a while. The announcement of a new CEO and CFO will also serve as sparks to send the stock higher. I expect to see a big jump in the number of PCM tests ordered-----and PAYED FOR---in the next ER, and that number should rise multiple-fold for many quarters to come-----or until the company is bought for it's unique technology, science, IP, and REVENUE potential.

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Apr 14, 2016 8:55 AM Flag

    This poster has been posting negatively about TROV for a few years. Pops up every now and then and has missed many opportunities to make money on the stock. He also is in denial of the fact that they have a UNIQUE diagnostic test with tremendous utility and value in the oncology treatment market as well as dozens of patents validating and protecting their IP. He also prefers to ignore all of the data published in PEER-REVIEWED journals that keeps verifying the accuracy and precision of the PCM platform-----and now he is ignoring the insurance panel inclusions that are now covering roughly half of all Americans-----and growing. He will still be saying the same things right up until the company is bought for $25/share(still a bargain to an acquirer at $750 million)

    Sentiment: Strong Buy

  • mgm2020 mgm2020 Apr 14, 2016 8:43 AM Flag

    Joe--you don't understand what's going on here and driving the stock higher. Has the FDA EVER rejected a drug following a near unanimous ADCOM vote to approve saying thagt the benefits outweighed the risk? NO. When was the last time that a company brought to market a drug for a condition with tremendous unmet need and hundreds of thousands of patients as well as their caregivers suffering-----with NO APPROVED COMPETITON? And when have you seen the largest shareholders of a company---with a seat on the BOD---BUY another MILLION shares of the stock a month before the PDUFA?? ACAD will rocket out of the gate and I believe that there are still many on the sidelines waiting to BUY once Nuplazid is approved. This is nothing like KERX or any other biotech/pharma company because of the unique nature of the drug and it's enormous market just waiting for it's approval.

    Sentiment: Strong Buy

KERX
6.09+0.23(+3.92%)10:35 AMEDT